These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21826262)

  • 1. Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls.
    Luckman SP; Gilhus NE; Romi F
    Autoimmune Dis; 2011; 2011():151258. PubMed ID: 21826262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum matrix metalloproteinase-3 levels are elevated in myasthenia gravis.
    Romi FR; Gilhus NE; Luckman SP
    J Neuroimmunol; 2008 Mar; 195(1-2):96-9. PubMed ID: 18262287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of matrix metalloproteinases: implications in clinical neurology.
    Romi F; Helgeland G; Gilhus NE
    Eur Neurol; 2012; 67(2):121-8. PubMed ID: 22262194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
    Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
    J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases in myasthenia gravis.
    Helgeland G; Petzold A; Luckman SP; Gilhus NE; Plant GT; Romi FR
    Eur Neurol; 2011; 65(1):53-8. PubMed ID: 21212676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells.
    Ding HL; Guo Y; Xu MT; Li HY; Fu ZZ
    Chin Med J (Engl); 2007 Nov; 120(21):1886-9. PubMed ID: 18067760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Increased Matrix Metalloproteinase-9 (MMP-9) Levels with Hyperglycaemia Incidence in Acute Ischemic Stroke Patients.
    Setyopranoto I; Malueka RG; Panggabean AS; Widyadharma IPE; Sadewa AH; Lamsudin R; Wibowo S
    Open Access Maced J Med Sci; 2018 Nov; 6(11):2067-2072. PubMed ID: 30559862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis.
    Alvarez B; Ruiz C; Chacón P; Alvarez-Sabin J; Matas M
    J Vasc Surg; 2004 Sep; 40(3):469-75. PubMed ID: 15337875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients.
    Trentini A; Castellazzi M; Cervellati C; Manfrinato MC; Tamborino C; Hanau S; Volta CA; Baldi E; Kostic V; Drulovic J; Granieri E; Dallocchio F; Bellini T; Dujmovic I; Fainardi E
    Dis Markers; 2016; 2016():3672353. PubMed ID: 27555667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
    McGirt MJ; Lynch JR; Blessing R; Warner DS; Friedman AH; Laskowitz DT
    Neurosurgery; 2002 Nov; 51(5):1128-34; discussion 1134-5. PubMed ID: 12383357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment.
    Montaner J; Alvarez-Sabín J; Molina C; Anglés A; Abilleira S; Arenillas J; González MA; Monasterio J
    Stroke; 2001 Aug; 32(8):1759-66. PubMed ID: 11486102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders.
    Ohno K; Ohkawara B; Ito M
    Expert Opin Ther Targets; 2017 Oct; 21(10):949-958. PubMed ID: 28825343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.
    Rivner MH; Quarles BM; Pan JX; Yu Z; Howard JF; Corse A; Dimachkie MM; Jackson C; Vu T; Small G; Lisak RP; Belsh J; Lee I; Nowak RJ; Baute V; Scelsa S; Fernandes JA; Simmons Z; Swenson A; Barohn R; Sanka RB; Gooch C; Ubogu E; Caress J; Pasnoor M; Xu H; Mei L
    Muscle Nerve; 2020 Sep; 62(3):333-343. PubMed ID: 32483837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies.
    Huang CY; Tseng KC; Lin MN; Tsai JP; Su CC
    J Clin Pathol; 2015 Nov; 68(11):917-22. PubMed ID: 26246386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.
    de Bruyn M; Arijs I; Wollants WJ; Machiels K; Van Steen K; Van Assche G; Ferrante M; Rutgeerts P; Vermeire S; Opdenakker G
    Inflamm Bowel Dis; 2014 Jul; 20(7):1198-207. PubMed ID: 24871805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.
    Link J; Fredrikson S; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
    Ann Neurol; 1994 Feb; 35(2):197-203. PubMed ID: 7509140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease.
    Nakamura T; Ushiyama C; Suzuki S; Ebihara I; Shimada N; Koide H
    Am J Nephrol; 2000; 20(1):32-6. PubMed ID: 10644865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoreactive T and B cells in nervous system diseases.
    Sun JB
    Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.